Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alumis Inc. (ALMS : NSDQ)

• Company Description    Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 170

• Price / Volume Information    Yesterday's Closing Price: $4.72 Daily Weekly Monthly 20 Day Moving Average: 578,741 shares Shares Outstanding: 104.06 (millions) Market Capitalization: $491.18 (millions) Beta: -1.35 52 Week High: $12.29 52 Week Low: $2.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.31% 3.52% 12 Week -0.63% -4.75% Year To Date -39.95% -47.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 280 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-231-6625 fax: - ir@alumis.com http://www.alumis.com

• General Corporate Information    Officers Martin Babler - Chief Executive Officer; President and Director John Schroer - Chief Financial Officer Srinivas Akkaraju - Director Alan B. Colowick - Director Patrick Machado - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 022307102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 104.06 Most Recent Split Date: (:1) Beta: -1.35 Market Capitalization: $491.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 94.94% vs. Previous Quarter: 35.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -84.67% ROE 09/30/25 - - 06/30/25 - -119.15 03/31/25 - -406.27 ROA 09/30/25 - - 06/30/25 - -92.50 03/31/25 - -107.29 Current Ratio 09/30/25 - - 06/30/25 - 6.05 03/31/25 - 3.73 Quick Ratio 09/30/25 - - 06/30/25 - 6.05 03/31/25 - 3.73 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -1,177.16 03/31/25 - -1,974.51 Book Value 09/30/25 - - 06/30/25 - 4.66 03/31/25 - 3.09 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©